Glaucoma Clinical Trial
Official title:
SD-OCT Multimodal Analysis in GLaucoma
Glaucoma is the first cause of irreversible blindness worldwide with more than 60 millions
people affected in 2010. It is defined as a neurodegenerative disease characterized by a
progressive loss of retinal ganglion cells (RGC), visual field deterioration and optic nerve
excavation. Intraocular pressure (IOP) is the most common risk factor. Despite its severity,
its impact on quality of life and an existing treatment that can delay visual field damages,
there is no recommended strategy to screen the disease. Clinical evaluation of optic nerve
head excavation performed either by ophthalmologists or glaucoma specialists is highly
inter-observer dependent and limits its accuracy to diagnose glaucoma. Additionally, up to 30
to 40% of nerve fiber layer may be lost before detecting first visual field defects, thus
making this tool not accurate enough for screening purposes.
Spectral-Domain Optical coherence tomography (SD-OCT) imaging technology allows precise and
reproducible measurements of optic nerve head structures and retinal layers mainly related to
the speed of acquisition and an axial resolution of 5 microns. New SD-OCT parameters have
been developed to improve its diagnostic accuracy for glaucoma disease. The investigators
therefore investigate performances of SD-OCT to discriminate glaucoma patients and controls.
All subjects will undergo SD-OCT imaging (Spectralis™ OCT, Version 6.3, Heidelberg
Engineering, Germany) and other study procedures in one single visit. All examinations
performed on the subjects are non-significant risk.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
| Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
| Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
| Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
| Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
| Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
| Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
| Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
| Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
| Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
| Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
| Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
| Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
| Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
| Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
| Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
| Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A |